Featured Content
Top Myeloma Journal Articles for the Week of June 28, 2021
Here are the top journal articles from the week of June 24, 2021 as selected by the MYELOMA360 staff. First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness...
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Myeloma News
Analyzing Survival Outcomes With Ixazomib-Rd in Relapsed/Refractory Multiple Myeloma
Source: Multiple Myeloma – ASH Clinical News While treatment with ixazomib, lenalidomide, and dexamethasone (ixazomib-Rd) was shown to improve progression-free survival, recent long-term findings from the phase III TOURMALINE-MM1 trial published in the Journal of...
Isatuximab Plus Carfilzomib and Dexamethasone Improves PFS in Relapsed/Refractory MM
Source: Multiple Myeloma – ASH Clinical News Recent results suggest that in patients with relapsed multiple myeloma (MM), combination therapy consisting of carfilzomib and dexamethasone (Kd) plus isatuximab is associated with improvements in progression-free survival...
Lenalidomide and Pomalidomide: Immunomodulating Drug Therapies in Multiple Myeloma
Source: Pharmacy Times articles The American Cancer Society estimates that oncologists will diagnose about 34,920 new cases of multiple myeloma in 2021 with about 12,410 deaths expected to occur. Read More
Ixazomib-Based Triple Regimen May Increase Survival for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
Source: Myeloma – Hematology Advisor For the treatment of transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM), the oral proteasome inhibitor ixazomib added to continuous lenalidomide-dexamethasone (Rd) treatment resulted in a nonstatistically...
Adding Ixazomib to Lenalidomide and Dexamethasone Doesn’t Improve Overall Survival in Rel/Ref Multiple Myeloma
Source: Myeloma – Hematology Advisor Ixazomib plus lenalidomide and dexamethasone (Rd) did not improve overall survival (OS), when compared with placebo plus Rd, in patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
Venetoclax Response May Not Be Predicted by t(11;14) in Patients With Myeloma
Source: Myeloma – Hematology Advisor Despite previous evidence to the contrary, research published in Blood suggests that translocation (t) (11;14) and CCND1 do not directly affect the likelihood of response to venetoclax among patients with multiple myeloma. Multiple...
Updates in Prevention, Treatment of Cytokine Release Syndrome, Neurologic Toxicities for Patients With Multiple Myeloma
Source: Pharmacy Times articles Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss the updates in the prevention and treatment of cytokine release syndrome and neurologic toxicities for patients with multiple myeloma. Read...
Serial MRD Measurements Predict Risk of Progression in Multiple Myeloma Patients on Maintenance
Source: Myeloma – Hematology Advisor Among patients with multiple myeloma (MM) receiving continuous lenalidomide maintenance, the risk of progression is lower for those with persistent minimal residual disease (MRD) than for those who lose MRD negativity, according to...
Subcutaneous Daratumumab Associated With Reduced Active Provider Time for Patients With Multiple Myeloma
Source: Myeloma – Hematology Advisor Subcutaneous daratumumab (DARA SC) requires less active healthcare provider (HCP) time and may be a more efficient method for administering the drug, according to survey results published in ClinicoEconomics and Outcomes Research....
Daratumumab Plus Pomalidomide and Dexamethasone Improved PFS in Rel/Ref Multiple Myeloma
Source: Myeloma – Hematology Advisor Adding daratumumab (dara) to pomalidomide and dexamethasone (pom-dex) improved progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (MM), according to study results published in The Lancet Oncology....
Recent Publications
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.ABSTRACTBACKGROUND: CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two...
Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis
Int J Mol Sci. 2021 Jul 13;22(14):7470. doi: 10.3390/ijms22147470.ABSTRACTMultiple myeloma (MM) is considered to be the second most common blood malignancy and it is characterized by abnormal proliferation and an accumulation of malignant plasma cells in the bone...
Myeloma Bone Disease: A Comprehensive Review
Int J Mol Sci. 2021 Jun 8;22(12):6208. doi: 10.3390/ijms22126208.ABSTRACTMultiple myeloma (MM) is a neoplastic clonal proliferation of plasma cells in the bone marrow microenvironment, characterized by overproduction of heavy- and light-chain monoclonal proteins...
Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma
Zhonghua Zhong Liu Za Zhi. 2021 Jun 23;43(6):657-665. doi: 10.3760/cma.j.cn112152-20200415-00347.ABSTRACTObjective: To design the fourth-generation chimeric antigen receptor-T (CAR-T) cells that secrete interleukin-7 (IL7) and chemokine C legend 19 (CCL19) on the...
Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma
Blood Adv. 2021 Jul 13;5(13):2753-2759. doi: 10.1182/bloodadvances.2020004131.ABSTRACTMultiple myeloma (MM) is a heterogeneous disease that may be evaluated by a broad array of imaging and laboratory techniques to measure disease activity and predict prognosis....
Serum Protein Electrophoresis and Immunofixation Electrophoresis Detection in Multiple Myeloma
J Coll Physicians Surg Pak. 2021 Jul;30(7):864-867. doi: 10.29271/jcpsp.2021.07.864.ABSTRACTThe objective of this study was to investigate the diagnostic significance of serum protein electrophoresis and immunofixation electrophoresis detection in diagnosis of...
Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma
Eur J Radiol. 2021 Aug;141:109793. doi: 10.1016/j.ejrad.2021.109793. Epub 2021 May 27.ABSTRACTImaging in hematological diseases has evolved extensively over the past several decades. Positron emission tomography/computed tomography (PET/CT) with of 2-[18...
Identification of hub genes with prognostic values in multiple myeloma by bioinformatics analysis
Hematology. 2021 Dec;26(1):453-459. doi: 10.1080/16078454.2021.1943617.ABSTRACTPURPOSE: Multiple myeloma (MM) is a malignant disease with abnormal proliferation of clonal plasma cells. Hypoxia is an important factor in the pathogenesis and development of MM. However,...
